Annexin VI-mediated loss of spectrin during coated pit budding is coupled to delivery of LDL to lysosomes.
Previously we reported that annexin VI is required for the budding of clathrin-coated pits from human fibroblast plasma membranes in vitro. Here we show that annexin VI bound to the NH2-terminal 28-kD portion of membrane spectrin is as effective as cytosolic annexin VI in supporting coated pit budding. Annexin VI-dependent budding is accompanied by the loss of approximately 50% of the spectrin from the membrane and is blocked by the cysteine protease inhibitor N-acetyl-leucyl-leucyl-norleucinal (ALLN). Incubation of fibroblasts in the presence of ALLN initially blocks the uptake of low density lipoprotein (LDL), but the cells recover after 1 h and internalize LDL with normal kinetics. The LDL internalized under these conditions, however, fails to migrate to the center of the cell and is not degraded. ALLN-treated cells have twice as many coated pits and twofold more membrane clathrin, suggesting that new coated pits have assembled. Annexin VI is not required for the budding of these new coated pits and ALLN does not inhibit. Finally, microinjection of a truncated annexin VI that inhibits budding in vitro has the same effect on LDL internalization as ALLN. These findings suggest that fibroblasts are able to make at least two types of coated pits, one of which requires the annexin VI-dependent activation of a cysteine protease to disconnect the clathrin lattice from the spectrin membrane cytoskeleton during the final stages of budding.
Kamal
A
A
Department of Cell Biology and Neuroscience, University of Texas Southwestern Medical Center, Dallas, Texas 75235, USA.
Ying
Y
Y
Anderson
R G
RG
D017317:Annexin A6 / Q000502:physiology*; D002966:Clathrin / Q000378:metabolism; D003034:Coated Pits, Cell-Membrane / Q000502:physiology*; D015853:Cysteine Proteinase Inhibitors / Q000494:pharmacology; D003599:Cytoskeleton / Q000502:physiology; D004705:Endocytosis / Q000187:drug effects / Q000502:physiology; D005347:Fibroblasts; D006801:Humans; D007976:Leupeptins / Q000494:pharmacology; D008077:Lipoproteins, LDL / Q000378:metabolism*; D008247:Lysosomes / Q000378:metabolism*; D008565:Membrane Proteins / Q000378:metabolism; D008856:Microscopy, Fluorescence; D010446:Peptide Fragments / Q000378:metabolism; D011485:Protein Binding / Q000502:physiology; D011994:Recombinant Proteins / Q000378:metabolism; D013049:Spectrin / Q000378:metabolism*
D017317:Annexin A6; D002966:Clathrin; D015853:Cysteine Proteinase Inhibitors; D007976:Leupeptins; D008077:Lipoproteins, LDL; D008565:Membrane Proteins; D010446:Peptide Fragments; D011994:Recombinant Proteins; C063261:acetylleucyl-leucyl-norleucinal; D013049:Spectrin